ES2184762T3 - Allquil bencilaminoquinuclidinas sustituidas con heteroatomos como antagonista de la sustancia p'. - Google Patents

Allquil bencilaminoquinuclidinas sustituidas con heteroatomos como antagonista de la sustancia p'.

Info

Publication number
ES2184762T3
ES2184762T3 ES94914619T ES94914619T ES2184762T3 ES 2184762 T3 ES2184762 T3 ES 2184762T3 ES 94914619 T ES94914619 T ES 94914619T ES 94914619 T ES94914619 T ES 94914619T ES 2184762 T3 ES2184762 T3 ES 2184762T3
Authority
ES
Spain
Prior art keywords
sub
sup
rent
replaced
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94914619T
Other languages
English (en)
Inventor
Kunio Satake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2184762T3 publication Critical patent/ES2184762T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PRESENTAN COMPUESTOS UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL Y OTRAS ENFERMEDADES, DE LA FORMULA (I) ASI COMO LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS; EN DONDE R ES ALQUILO C{SUB, 1-6}; X ES ALQUILO C{SUB, 1-6} QUE TIENE UNO O MAS SUSTITUYENTES QUE INCLUYEN AL MENOS UN HETEROATOMO; AR{SUP, 1} Y AR{SUP, 2} SON CADA UNA INDEPENDIENTEMENTE ARILO OPCIONALMENTE SUSTITUIDO POR UNO O MAS ALQUILO C{SUB, 1-6}, ALQUILTIO C{SUB, 1-6}, HALOGENO, CIANO, NITRO, FENOXIDO, MONOALQUILAMINO C{SUB, 1-6}, DIALQUILAMINO C{SUB, 1-6}, ALQUIL C{SUB, 1-6} HALOSUSTITUIDO, O ALCOXIDO C{SUB, 1-6} HALOSUSTITUIDO; Y ES HIDROGENO, ALQUIL C{SUB, 1-6} ALQUENIL C{SUB, 2-6}, CICLOALQUIL C{SUB, 3-8}, Z-(CH{SUB, 2}{SUB, P-}, O W-(CH{SUB, 2}){SUB, M}CHR{SUP, 2}(CH{SUB, 2}{SUB, N}-NR{SUP, 1}CO- EN DONDE Y ESTA SUSTITUIDA EN LA POSICION 4-, 5- O 6- EN UN ANILLO DE QUINUCLIDINA; R{SUP, 1} ES HIDROGENO, ALQUIL C{SUB, 1-6}, BENCIL O -(CH{SUB, 2}{SUB, R}-W; R{SUB, 2} ES HIDROGENO O ALQUIL C{SUB, 1-6} QUE PUEDE SER SUSTITUIDA POR UN HIDROXIDO, AMINO, METILTIO, METILMERCAPTO, BENCILO, 4-HIDROXIBENCILO, 3-INDOLILMETILO O (CH{SUB, 2}{SUB, R}; R{SUB, 1} PUEDE FORMAR UN ANILLO CON R{SUB, 2}; Z ES ALCOXIDO C{1-6}, -CONR{SUP, 4}R{SUP, 5}, -CO{SUB, 2}R{SUP, 4}, -CHR{SUP, 4}OR{SUP, 5}, -CHR{SUP, 4}NR{SUP, 5}R{SUP, 6}, -COR{SUP, 4}, -CONR{SUP, 4}OR{SUP, 5} O OPCIONALMENTE SUSTITUIDO POR ARIL; CADA W ES INDEPENDIENTEMENTE CIANO, HIDROXIMETILO, ALCOXIMETILO C{SUB, 2-6}, AMINOMETILO, MONOALQUILAMINOMETILO C{SUB, 1-6}, DIALQUILAMINOMETILO C{SUB, 16}, CARBOXILO, CARBAMOILO O ALCOXICARBONILO C{SUB, 1-6}; R{SUP, 4}, R{SUP, 5} Y R{SUP, 6} SON INDEPENDIENTEMENTE HIDROGENO, ALQUIL C{SUB, 1-6}, ALCOXIDO C{SUB, 1-6}, CICLOALQUILO C{SUB, 38} U OPCIONALMENTE ARIL SUSTITUIDO O UN GRUPO HETEROCICLICO; P ES 0-6; Y M, N Y R SON CADA UNA INDEPENDIENTEMENTE, 0-3.
ES94914619T 1993-05-19 1994-05-13 Allquil bencilaminoquinuclidinas sustituidas con heteroatomos como antagonista de la sustancia p'. Expired - Lifetime ES2184762T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11710293 1993-05-19

Publications (1)

Publication Number Publication Date
ES2184762T3 true ES2184762T3 (es) 2003-04-16

Family

ID=14703456

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94914619T Expired - Lifetime ES2184762T3 (es) 1993-05-19 1994-05-13 Allquil bencilaminoquinuclidinas sustituidas con heteroatomos como antagonista de la sustancia p'.

Country Status (12)

Country Link
US (1) US5741797A (es)
EP (1) EP0699199B1 (es)
AT (1) ATE228129T1 (es)
AU (1) AU6691094A (es)
CA (1) CA2161886C (es)
DE (1) DE69431751T2 (es)
DK (1) DK0699199T3 (es)
ES (1) ES2184762T3 (es)
FI (1) FI942314A7 (es)
IL (1) IL109646A0 (es)
PT (1) PT699199E (es)
WO (1) WO1994026740A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014845A1 (en) * 1994-11-10 1996-05-23 Pfizer Inc. Nk-1 receptor antagonists for the treatment of eye disorders
EP0780375B1 (en) 1995-12-21 2002-09-11 Pfizer Inc. 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
PL367944A1 (en) * 2001-07-20 2005-03-07 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
EP1556054A4 (en) * 2002-05-29 2007-09-05 Univ California ANTAGONIZING NK1 RECEPTORS RESTRICT DRUG ABUSE
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
UA26401C2 (uk) * 1991-05-22 1999-08-30 Пфайзер Інк. Заміщеhі 3-аміhохіhуклідиhи
AU657552B2 (en) * 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
DE69213451T2 (de) * 1991-06-20 1997-01-09 Pfizer Inc., New York Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
US5294744A (en) * 1993-04-20 1994-03-15 Pfizer Inc. Formylation process for aromatic aldehydes
JP3326489B2 (ja) * 1996-02-10 2002-09-24 好高 青山 部品供給ロッド装置とそれによる供給方法
JPH09221677A (ja) * 1996-02-14 1997-08-26 Kansai Coke & Chem Co Ltd 石炭の高温予熱方法
JPH09319064A (ja) * 1996-05-29 1997-12-12 Konica Corp 写真製品の生産方法及び生産装置

Also Published As

Publication number Publication date
DE69431751T2 (de) 2003-04-03
FI942314A0 (fi) 1994-05-18
CA2161886C (en) 1999-12-07
WO1994026740A1 (en) 1994-11-24
CA2161886A1 (en) 1994-11-24
ATE228129T1 (de) 2002-12-15
EP0699199B1 (en) 2002-11-20
AU6691094A (en) 1994-12-12
PT699199E (pt) 2003-01-31
DK0699199T3 (da) 2002-12-16
DE69431751D1 (de) 2003-01-02
FI942314L (fi) 1994-11-20
US5741797A (en) 1998-04-21
FI942314A7 (fi) 1994-11-20
EP0699199A1 (en) 1996-03-06
IL109646A0 (en) 1994-08-26

Similar Documents

Publication Publication Date Title
ES2184762T3 (es) Allquil bencilaminoquinuclidinas sustituidas con heteroatomos como antagonista de la sustancia p'.
MX9301634A (es) Quinuclidinas peptidicas.
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2113368T3 (es) Antagonistas de serotonina.
ES2165505T3 (es) Compuestos aromaticos y composiciones farmaceuticas que los contienen.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
ES2157353T3 (es) Oximas de la rapamicina en posicion 42 e hidroxilaminas.
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
ES2065691T3 (es) Derivados de quinuclidina.
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
ES2052675T3 (es) 3-(4-piperazinil-sustituido en 1)butil)-4-tiazolidinonas, un procedimiento para su preparacion y su uso como medicamentos.
PT86980A (pt) Process for preparing benzodiazepine analogs
ES2083569T3 (es) Nuevos derivados de ariletenileno y procedimiento para su preparacion.
ES2096560T3 (es) Compuestos de benzocicloheptapiridina sustituida con fluor, composiciones y metodos para uso como compuestos antihistaminicos.
ES2054627T3 (es) Indolinas 3,3-disustituidas.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
ES2158840T3 (es) Nuevos analogos de adenosina carbociclicos utiles como inmunosupresores.
ES2167544T3 (es) Dioxidos de benzotiazina como antagonistas de la endotelina.
ES2164366T3 (es) Derivados de la distamicina acriloil sustituidos, procedimiento de fabricacion asociado y su utilizacion como agentes antitumorales y antivirales.
ES2155827T3 (es) 4-carboxiimidazoles como antagonistas de la angiotensina ii y su uso terapeutico.
ES2110260T3 (es) Androstenonas.
ES2079570T3 (es) Nuevas pirido(2,3-f)(1,4)tiazepinas y pirido(3,2-b)(1,5)benzotiazepinas.
ES2071479T3 (es) Derivados de indano.